Cero Therapeutics Holdings, Inc. financial data

Symbol
CERO, CEROW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
201 Haskins Way, Suite 230, South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
PHOENIX BIOTECH ACQUISITION CORP. (to 2/14/2024)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -67.3 % +60.2%
Return On Equity 32.6 % -22.2%
Return On Assets -67.7 % -804%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.7M shares
Common Stock, Shares, Outstanding 9.07M shares
Common Stock, Value, Issued 907 USD +931%
Weighted Average Number of Shares Outstanding, Basic 16.2M shares +78.7%
Weighted Average Number of Shares Outstanding, Diluted 16.2M shares +78.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.71M USD +128%
General and Administrative Expense 5.75M USD +43%
Operating Income (Loss) -10.1M USD -113%
Nonoperating Income (Expense) 2.7M USD +740%
Net Income (Loss) Attributable to Parent -5.08M USD -7.93%
Earnings Per Share, Basic -0.15 USD/shares +34.8%
Earnings Per Share, Diluted -0.15 USD/shares +34.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 96.9K USD -79.6%
Assets, Current 4.25M USD
Property, Plant and Equipment, Net 739K USD
Operating Lease, Right-of-Use Asset 1.84M USD
Assets 7.37M USD -47.8%
Accounts Payable, Current 6.35M USD
Employee-related Liabilities, Current 243K USD
Accrued Liabilities, Current 1.16M USD
Liabilities, Current 8.78M USD +99%
Operating Lease, Liability, Noncurrent 1.07M USD
Liabilities 9.85M USD -27.3%
Retained Earnings (Accumulated Deficit) -67.4M USD -407%
Stockholders' Equity Attributable to Parent -2.48M USD +81.3%
Liabilities and Equity 7.37M USD -47.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 45.4M shares
Common Stock, Shares, Issued 9.07M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.65M USD +3366%
Deferred Tax Assets, Valuation Allowance 608K USD +1.81%
Deferred Tax Assets, Gross 608K USD +1.81%
Operating Lease, Liability 1.89M USD
Depreciation 114K USD -0.94%
Lessee, Operating Lease, Liability, to be Paid 2.12M USD
Operating Lease, Liability, Current 821K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 726K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 990K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 228K USD
Preferred Stock, Shares Issued 4M shares
Preferred Stock, Shares Authorized 1M shares 0%
Additional Paid in Capital 57.6M USD
Share-based Payment Arrangement, Expense 30K USD -97.9%
Interest Expense 14.4K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%